Teva announces data from fourth interim analysis of PEARL study of AJOVY

Teva Pharmaceutical announced new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY that may challenge the rationale for treatment pauses with calcitonin gene-related peptide monoclonal antibodies mandated or recommended by some reimbursement authorities after one year of continuous use. The sub-analysis from the PEARL real world data explored the impact of fremanezumab treatment cessation and reinitiation on monthly migraine days in adult patients with episodic or chronic migraine. The data1 show that pausing treatment of fremanezumab, a CGRP-pathway mAb, may result in a potential rise in monthly migraine days following treatment cessation and reduced effectiveness upon reinitiation compared to the first treatment cycle, adding to the burden of the individual living with migraine: Over 40% of patients experienced a rapid worsening of their migraine at Months 1 and 2 post-cessation. The proportion of patients achieving greater than=50% reduction in MMD at Month 1 and Month 3, respectively, was 49.0% and 58.9% in the first treatment period versus a lower effectiveness of 35.7% and 45.5% in the second treatment period.